BIOCON LTD. - 532523 - Company Statement
Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.28-04-2021
28-04-2021
Biocon Biologics, Viatris get EC nod for biosimilar drug Bevacizumab
The drug is used in treatment of cancer as part of a specific regimen26-04-2021
Biocon Ltd - 532523 - Company Statement
Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab.26-04-2021
Biocon Ltd - 532523 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2020-21 issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V Sreedharan and Associates, Practicing Company Secretaries, Bengaluru.24-04-2021
How to earn 13,000-profit with bull-call spread on Biocon
Strong surge seen on open positions in the last few days17-04-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice of Board Meeting - Newspaper Advertisement16-04-2021
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice of Board Meeting - Newspaper Advertisement16-04-2021
Biocon Ltd - 532523 - Shareholding for the Period Ended March 31, 2021
Biocon Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here16-04-2021
BIOCON LTD. - 532523 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 047470 Name of the Signatory :- Mayank VermaDesignation :- Company Secretary and Compliance Officer15-04-2021